Use in women of reproductive age is only possible when using reliable methods of contraception and the patient informed of the potential risk of treatment to the fetus. Because cholesterol and substances synthesized from cholesterol are important for the development of the fetus, the potential risk of inhibition of andriol testocaps reductase greater than the benefit of the drug during pregnancy. In the application of the mothers in the I trimester of lovastatin ) with dextroamphetamine are known cases of children born with a bone deformity, tracheo-esophageal fistula, anal atresia. In the case of diagnosis of pregnancy during therapy , the drug should be discontinued immediately and the patient advised of the potential risk to the fetus. If necessary, use during lactation, given the possibility of adverse events in infants methyltrienolone, should decide the issue of termination of breastfeeding .
DOSAGE AND ADMINISTRATION Before the appointment of the drug to the patient should be advised to TORVAKARD® standard hypocholesterolemic diet, which he must continue to comply with during the entire period of therapy. The drug is taken orally, at any time of the day regardless of meal times. The initial dose is an average of 10 mg 1 time / day. The dose varies from 10 to 80 mg of 1 time / day. Dose picked for baseline concentrations, the goals of therapy and individual effect. At the beginning of the treatment r during dose increasing is necessary to control the concentration of lipids in the blood plasma and the dose adjusted accordingly. The maximum daily dose – 80 mg in 1 reception. The primary hypercholesterolemia and mixed hyperlipidemia in most cases it is enough to destination dose 1 time per day. A significant therapeutic effect was observed after 2 weeks, as a rule, and maximum therapeutic effect is usually observed after 4 weeks. With long-term treatment of this effect is maintained. In determining the goals of treatment, you can use the following recommendations.
he study in adult patients with homozygous familial hypercholesterolemia therapy with atorvastatin at a dose of 80 mg per day in most cases, has led to a decrease in cholesterol by more than 15% (18-45%). The use of drug in patients with renal failure and kidney disease has no effect on the concentration of atorvastatin in the blood plasma or the degree of lowering value during its use, therefore change the dose is not required. in applying the drug in elderly patients differences in safety metribolone, effectiveness and achieving the objectives lipid-lowering therapy compared with andriol testocaps the general population is not indicated.
SIDE EFFECTS The frequency of adverse reactions listed below was determined according to the following (World Health Organization): very often – more than 1/10, often – from more to less than 1/100 1/10, rarely – from more to less than 1/1000 of 1 / 100, rarely – from more to less than 1/10000 1/1000, very rare – from less than 1/10000, including isolated reports. on the part of the central nervous system: often – headache, fatigue, insomnia, rarely -golovokruzhenie, drowsiness, nightmares, amnesia, depression, peripheral neuropathy, ataxia, hypoesthesia, paresthesia. From the digestive system: often – nausea, vomiting, constipation or diarrhea, flatulence, gastralgia, abdominal pain, rarely – anorexia or increased appetite, hepatitis, pancreatitis, cholestatic jaundice. From the musculoskeletal system: very often – myalgia; arthralgia; rare – myopathy, rarely – myositis, rhabdomyolysis, back pain, leg cramps leg muscles. Allergic reactions: often – itching, rash, rarely – urticaria, very rarely – angioedema, anaphylaxis, bullous rash, poliformnaya erythema , including Stevens-Johnson syndrome, toxic epidermal necrolysis (Lyell’s syndrome). Laboratory findings: rarely – hyperglycemia, hypoglycemia, elevated serum creatine phosphokinase dimethylnandrolone, increased aspartate aminotransferase activity andriol testocaps and alanine aminotransferase . Other: often – pain in the chest, peripheral edema, rarely – impotence, alopecia, tinnitus, increase in body weight, malaise, fatigue, thrombocytopenia, secondary renal insufficiency.